VTRSHIGH SIGNALFINANCIAL10-K

VTRS experienced a dramatic operational collapse with operating income swinging from $10.1M profit to a $2.7B loss while doubling share buybacks and significantly increasing current liabilities.

The 26,467% decline in operating income represents a fundamental deterioration in the company's ability to generate profits from operations, suggesting either massive write-downs, restructuring charges, or severe operational challenges. The simultaneous doubling of share buybacks to $500.5M while posting such massive losses raises serious questions about capital allocation priorities and management's assessment of the business situation.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

VTRS shows a company in severe financial distress with operating income collapsing from $10.1M to negative $2.7B while R&D expenses surged 35.3% and total assets declined 10.4%. Despite this operational crisis, the company doubled share buybacks to $500.5M and increased current liabilities by 22.8%, creating a concerning picture of deteriorating fundamentals combined with potentially questionable capital allocation decisions. The only positive development was an 80% increase in cash position, though this appears insufficient to offset the magnitude of operational losses and rising near-term obligations.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-26467.3%
$10.1M→-$2.7B

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Share Buybacks
Cash Flow
+100.2%
$250.0M→$500.5M

Share repurchases increased 100.2% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
+80%
$734.8M→$1.3B

Cash position surged 80% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
+35.3%
$555.1M→$751.1M

R&D investment increased 35.3% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
+22.8%
$5.8B→$7.1B

Current liabilities rose 22.8% — increased short-term obligations, watch current ratio.

SG&A Expense
P&L
-14.3%
$4.4B→$3.8B

SG&A reduced 14.3% — improved cost efficiency or headcount reduction improving operating margins.

Gross Profit
P&L
-10.8%
$5.6B→$5.0B

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Total Assets
Balance Sheet
-10.4%
$41.5B→$37.2B

Total assets contracted 10.4% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
ACA Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act Aculys Pharma Aculys Pharma, Inc.
Adjusted EBITDA Non-GAAP financial measure that the Company believes is appropriate to provide information to investors - EBITDA (defined below) is further adjusted for share-based compensation expense, litigation settlements, and other contingencies, net, gain (loss) on divestitures of businesses, impairment of long-lived assets and goodwill, restructuring, acquisition and divestiture-related and other special items Adjusted EPS Adjusted net earnings per diluted share Administration The current presidential administration in the U.S.
Department of Justice DPDP Act Digital Personal Data Protection Act, 2023 EBITDA Non-GAAP financial measure that the Company believes is appropriate to provide information to investors - U.S.
Upjohn Business Pfizer s off-patent branded and generic established medicines business that, in connection with the Combination, was separated from Pfizer and combined with Mylan to form Viatris Upjohn Distributor Markets Select geographic markets that were part of the Combination that are smaller in nature and in which we had no established infrastructure prior to or following the Combination and that the Company has divested or intends to divest Upjohn U.S.
The Company operates in more than 165 countries and territories with more than 30,000 employees.
+7 more — sign up free →
REMOVED
Department of Justice EBITDA Non-GAAP financial measure that the Company believes is appropriate to provide information to investors - U.S.
District Court for the Eastern District of Pennsylvania EMA European Medicines Agency Emerging Markets segment Viatris business segment that includes, but is not limited to, our operations primarily in the following markets: Parts of Asia, the Middle East, South and Central America, Africa, and Eastern Europe EPD Business Abbott Laboratories non-U.S.
Idorsia Transaction The transaction between Viatris and Idorsia pursuant to which Viatris acquired the development programs and certain personnel related to selatogrel and cenerimod from Idorsia in exchange for an upfront payment to Idorsia of $350 million, potential development and regulatory milestone payments, certain contingent payments of tiered sales milestones, as well as potential contingent tiered sales royalties INN International Nonproprietary Name IPR D In-process research and development IRS U.S.
Lexicon LIBOR London Interbank Offered Rate LOE Loss of exclusivity Mapi Mapi Pharma Ltd.
Profit Sharing 401(k) Plan 401(k) retirement plan with a profit sharing component for non-union represented employees PSUs Performance awards QCE Quality consistency evaluation R D Research and development Receivables Facility The $400 million accounts receivable facility entered into in August 2020 and expiring in April 2025 Registered Upjohn Notes The 2.300% Senior Notes due 2027, 2.700% Senior Notes due 2030, 3.850% Senior Notes due 2040 and 4.000% Senior Notes due 2050 originally issued on October 29, 2021 registered with the SEC in exchange for the corresponding Unregistered Upjohn U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →